Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2011 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Other Non-Current Assets came in at $19.7 million in Q1 2026, up 306.12% YoY from $4.8 million in Q1 2025, and up 247.27% on a QoQ basis from $5.7 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Other Non-Current Assets data on file, last reported at $19.7 million in Q1 2026.
- Quarterly Other Non-Current Assets rose 306.12% year-over-year to $19.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.7 million (up 306.12% YoY) and the FY2025 annual result came in at $5.7 million, up 9.99% from the prior year.
- Other Non-Current Assets grew to $19.7 million in Q1 2026, from $5.7 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $19.7 million in Q1 2026 to a low of $80000.0 in Q4 2023.
- A 5-year average of $8.1 million and a median of $6.9 million in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets tumbled 98.82% — and 2024, when it surged 6346.25%.
- Tracing BCRX's Other Non-Current Assets over 5 years: stood at $6.8 million in 2022, then plunged by 98.82% to $80000.0 in 2023, then soared by 6346.25% to $5.2 million in 2024, then gained by 9.99% to $5.7 million in 2025, then surged by 247.27% to $19.7 million in 2026.
- The last three Other Non-Current Assets figures came in at $19.7 million (Q1 2026), $5.7 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 13.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.43 Bn | 2.08 Bn | 214.41 Mn | 19.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.56 Mn |
| Mar 31, 2026 | 19.70 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | 4.39 Mn |
| Jun 30, 2025 | 3.59 Mn |
| Mar 31, 2025 | 4.85 Mn |
| Dec 31, 2024 | 5.16 Mn |
| Sep 30, 2024 | 15.65 Mn |
| Jun 30, 2024 | 12.46 Mn |
| Mar 31, 2024 | 12.96 Mn |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | 11.46 Mn |
| Jun 30, 2023 | 6.95 Mn |
| Mar 31, 2023 | 7.05 Mn |
| Dec 31, 2022 | 6.81 Mn |
| Sep 30, 2022 | 6.80 Mn |
| Jun 30, 2022 | 6.98 Mn |
| Mar 31, 2022 | 7.21 Mn |
| Dec 31, 2021 | 6.47 Mn |
| Sep 30, 2021 | 5.19 Mn |